# US 2025/0084101 A1 · Compound for inhibiting and degrading irak4, and pharmaceutical composition and pharmaceutical application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084101 A1
- Document ID: US20250084101A1
- Status: Published application
- Kind: A1
- Application number: 18/726,753
- Filed: 2023-01-04
- Published: 2025-03-13
- Earliest claimed: 2022-01-04
- Assignees: Xizang Haisco Pharmaceutical Co., Ltd.
- Applicants: Xizang Haisco Pharmaceutical Co., Ltd.
- Inventors: Chen ZHANG; Yuting LIAO; Chenfei ZHAO; Yan YU; Pingming TANG; Junjie MA; Xiaogang CHEN; Shuai YUAN; Xinfan CHENG; Fei YE; Yao LI; Jia NI; Pangke YAN
- Web page: https://patentgrep.com/patent/US20250084101A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 413/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, and an intermediate thereof, and use thereof in IRAK4-related diseases such as an autoimmune disease, an inflammatory disease or cancer. B-L-K (I)

## Claims

### Claim 1

A compound or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, wherein the compound is a compound represented by general formula (I),
B-L-K (I);
L is selected from -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-;
Ak1, Ak2, Ak3, Ak4 and Ak5 are each independently selected from —(CH2)q—, O, —(CH2)qNRL—, NRLC═O, C═ONRL, C═O, —RLC═CRL, C═C or a bond;
RL is selected from H or C1-6 alkyl;
Cy1, Cy2, Cy3 and Cy4 are each independently selected from a bond, 4- to 7-membered mono-heterocyclic ring, 4- to 10-membered fused-heterocyclic ring, 5- to 12-membered spiro-heterocyclic ring, 7- to 10-membered bridged-heterocyclic ring, 3- to 7-membered monocycloalkyl, 4- to 10-membered fused cycloalkyl, 5- to 12-membered spiro cycloalkyl, 7- to 10-membered bridged cycloalkyl, 5- to 10-membered heteroaryl or 6- to 10-membered aryl, wherein the aryl, heteroaryl, cycloalkyl, mono-heterocyclic ring, fused-heterocyclic ring, spiro-heterocyclic ring or bridged-heterocyclic ring is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, C(═O)OH, CN, NH2, ═O, C1-4 alkyl, halogen-substituted C1-4 alkyl, hydroxyl-substituted C1-4 alkyl or C1-4 alkoxy, and the heteroaryl, mono-heterocyclic ring, fused-heterocyclic ring, spiro-heterocyclic ring or bridged-heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, or N;
B is selected from
B1 and B3 are each independently selected from C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S or N;
Rb1 and Rb7 are each independently selected from H, F, Cl, Br, I, ═O, OH, NH2, CN, CF3, C(—O) OH, CHF2, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, —(CH2)n—Rb21, —ORb21, —N(Rb21)2, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, —N(Rb21)2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl or Rb7a, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
Rb7a is selected from C1-4 alkyl, —C3-6 cycloalkyl, 4- to 10-membered heterocyclyl, —C1-4 alkylene-C3-6 cycloalkyl, —C1-4 alkylene 4- to 10-membered heterocyclyl, —O—C3-6 cycloalkyl, —O-4- to 10-membered heterocyclyl, —NH—C3-6 cycloalkyl, —NH-4- to 10-membered heterocyclyl, —N(C1-4 alkyl)-C3-6 cycloalkyl or —N(C1-4 alkyl)-4- to 10-membered heterocyclyl, wherein the Rb7a is optionally substituted with 1 to 4 substituents selected from H, F, Cl, Br, I, OH, —O, —N(Rb21)2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl or 4- to 10-membered heterocyclyl, and the heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
Rb2 and Rb6 are each independently selected from H, F, Cl, Br, I, ═O, OH, —C(═O)N(Rb21)2, —N(Rb21)2, CN, CF3, C(═O)OH, CHF2, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, —(CH2)n—Rb21, —ORb21, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, CF3, C(═O)OH, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
each Rb21 is independently selected from H, C1-6 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl or 4- to 10-membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, CF3, C(═O)OH, C1-4 alkyl, C3-6 cycloalkyl or C1-4 alkoxy, and the heteroaryl or heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
n is selected from 0, 1, 2, 3 or 4;
K is selected from
each Rk1 is independently selected from H, C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein the alkyl, cycloalkyl or heterocycloalkyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2, CN, CF3, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkyl;
Rk2 and Rk3 are each independently selected from H, F, Cl, Br, I, OH, ═O, NH2, CF3, CN, C(═O)OH, C(═O)NH2, C1-4 alkyl or C1-4 alkoxy, wherein the alkyl or alkoxy is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, or NH2;
or two Rk3 together with the carbon atoms or ring backbones to which they are directly attached form 3- to 6-membered carbocycle or 3- to 7-membered heterocycle, wherein the carbocycle or heterocycle is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, ═O, NH2, CN, C(═O)OH, C(═O)NH2, C1-4 alkyl or C1-4 alkoxy, and the heterocycle contains 1 to 4 heteroatoms selected from O, S or N;
q is selected from 0, 1, 2, 3 or 4;
n1, n2 and n6 are each independently selected from 0, 1, 2 or 3;
p2 and p3 are each independently selected from 0, 1, 2, 3 or 4;
optionally, 0 to 50 H of the compound represented by general formula (I) are replaced by 0 to 50 D.

### Claim 2 (depends on 1)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 1, wherein
Cy1, Cy2, Cy3 and Cy4 are each independently selected from a bond, 4- to 7-membered nitrogen-containing mono-heterocyclic ring, 4- to 10-membered nitrogen-containing fused-heterocyclic ring, 5- to 12-membered nitrogen-containing spiro-heterocyclic ring, 7- to 10-membered nitrogen-containing bridged-heterocyclic ring, 3- to 7-membered monocycloalkyl, 4- to 10-membered fused cycloalkyl, 5- to 12-membered spiro cycloalkyl, 7- to 10-membered bridged cycloalkyl, 5- to 10-membered heteroaryl or 6- to 10-membered aryl, wherein the mono-heterocyclic ring, fused-heterocyclic ring, bridged-heterocyclic ring, spiro-heterocyclic ring, cycloalkyl, aryl or heteroaryl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, C(═O)OH, CN, NH2, ═O, C1-4 alkyl, halogen-substituted C1-4 alkyl, hydroxyl-substituted C1-4 alkyl or C1-4 alkoxy, and the mono-heterocyclic ring, fused-heterocyclic ring, bridged-heterocyclic ring, spiro-heterocyclic ring or heteroaryl contains 1 to 4 heteroatoms selected from O, S, or N.

### Claim 3 (depends on 2)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 2, wherein
RL is selected from H, methyl or ethyl;
Cy1, Cy2, Cy3 and Cy4 are each independently selected from a bond or one of the following substituted or unsubstituted groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azacyclopentyl, piperidyl, morpholinyl, piperazinyl, phenyl, cyclopropyl-fused-cyclopropyl, cyclopropyl-fused-cyclobutyl, cyclopropyl-fused-cyclopentyl, cyclopropyl-fused-cyclohexyl, cyclobutyl-fused-cyclobutyl, cyclobutyl-fused-cyclopentyl, cyclobutyl-fused-cyclohexyl, cyclopentyl-fused-cyclopentyl, cyclopentyl-fused-cyclohexyl, cyclohexyl-fused-cyclohexyl, cyclopropyl-spiro-cyclopropyl, cyclopropyl-spiro-cyclobutyl, cyclopropyl-spiro-cyclopentyl, cyclopropyl-spiro-cyclohexyl, cyclobutyl-spiro-cyclobutyl, cyclobutyl-spiro-cyclopentyl, cyclobutyl-spiro-cyclohexyl, cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused-azetidinyl, cyclopropyl-fused-azacyclopentyl, cyclopropyl-fused-azacyclohexyl, cyclobutyl-fused-azetidinyl, cyclobutyl-fused-azacyclopentyl, cyclobutyl-fused-azacyclohexyl, cyclopentyl-fused-azetidinyl, cyclopentyl-fused-azacyclopentyl, cyclopentyl-fused-azacyclohexyl, cyclohexyl-fused-azetidinyl, cyclohexyl-fused-azacyclopentyl, cyclohexyl-fused-azacyclohexyl, azetidinyl-fused-azetidinyl, azetidinyl-fused-azacyclopentyl, azetidinyl-fused-azacyclohexyl, azacyclopentyl-fused-azacyclopentyl, azacyclopentyl-fused-azacyclohexyl, azacyclohexyl-fused-azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclobutyl-spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azacyclohexyl,
which, when substituted, is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2, C(═O)OH, CN, ═O, C1-4 alkyl, halogen-substituted C1-4 alkyl, hydroxyl-substituted C1-4 alkyl or C1-4 alkoxy;
B1 and B3 are each independently selected from pyrazolyl, oxazolyl, dioxazolyl, oxadiazolyl, triazolyl, imidazolyl, tetrazolyl, pyrrolyl, thienyl, thiazolyl, thiadiazolyl, pyridyl, phenyl, pyrazinyl, pyrimidyl, pyridazinyl, thienopyrazinyl, benzimidazolyl, pyridotriazolyl, pyrimidopyrazolyl, imidazopyridazinyl, pyridopyrazolyl, pyrrolopyridazinyl or
Rb1 and Rb7 are each independently selected from H, F, Cl, Br, I, ═O, OH, NH2, CN, CF3, CHF2, CH2F, methyl, ethyl, methoxy, ethoxy, phenyl, pyrrolyl, pyridyl, morpholinyl,
wherein the methyl, ethyl, methoxy, ethoxy, phenyl, pyrrolyl, pyridyl or morpholinyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, CN, CF3, NH2, NHC1-4 alkyl, N(C1-4 alkyl) 2, NHCH2C3-6 cycloalkyl, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl or Rb7a;
or Rb1 and Rb7 are each independently selected from azetidinyl, azacyclopentyl, piperidyl, piperazinyl, morpholinyl or 2-oxa-5-azabicyclo[2.2.1]heptanyl, wherein the Rb1 and Rb7 are optionally substituted with 1 to 4 substituents selected from F, Cl, Br, I, OH, ═O, CN, CF3, NH2, NHC1-4 alkyl, N(C1-4 alkyl) 2, NHCH2C3-6 cycloalkyl, halogen-substituted C1-4 alkyl, cyano-substituted C1-4 alkyl, —C1-4 alkylene-OH, C1-4 alkyl, C1-4 alkoxy, —CH2—O—C1-4 alkyl, —CH2—C3-6 cycloalkyl, —O—C3-6 cycloalkyl, —NH—C3-6 cycloalkyl, C3-6 cycloalkyl, —CH2-4- to 7-membered heterocycloalkyl, —O-4- to 7-membered heterocycloalkyl, —NH-4- to 7-membered heterocycloalkyl, or 4- to 7-membered heterocycloalkyl, and the heterocyclyl contains 1 to 4 heteroatoms selected from O, S, or N;
Rb2 and Rb6 are each independently selected from H, F, Cl, Br, I, ═O, CF3, CHF2, OH, NH2, NH(methyl), NH(ethyl), NH(propyl), NH(isopropyl), N(methyl)2, N(ethyl)2, CN, methyl, ethyl, methoxy, ethoxy, propoxy, isopropyloxy, morpholinyl, piperazinyl, pyrrolidyl, piperidyl or oxazolidinyl, wherein the methyl, ethyl, methoxy, ethoxy, propoxy, isopropyloxy, morpholinyl, piperazinyl, pyrrolidyl, piperidyl or oxazolidinyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, CN, CF3, C1-4 alkyl, C1-4 alkoxy or C3-6 cycloalkyl;
each Rk1 is independently selected from H, methyl, ethyl, propyl, isopropyl, ethenyl, propenyl, allyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azacyclopentyl, piperidyl, oxacyclobutyl, oxacyclopentyl or oxacyclohexyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azacyclopentyl, piperidyl, oxacyclobutyl, oxacyclopentyl or oxacyclohexyl is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, CN, CF3, C1-4 alkyl, C1-4 alkoxy, ethenyl, propenyl, allyl, ethynyl, propynyl, propargyl or C3-6 cycloalkyl;
Rk2 and Rk3 are each independently selected from H, F, Cl, Br, I, OH, ═O, NH2, CF3, CN, C(═O)OH, C(═O)NH2, methyl, ethyl, methoxy or ethoxy, wherein the methyl, ethyl, methoxy or ethoxy is optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH or NH2;
each p2 or p3 is independently selected from 0, 1 or 2.

### Claim 4 (depends on 3)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 3, wherein
Cy1, Cy2, Cy3 and Cy4 are each independently selected from a bond or one of the following substituted or unsubstituted groups:
which, when substituted, is optionally further substituted with 0 to 4 substituents selected from H, F, CF3, methyl, ═O, hydroxymethyl, C(═O)OH, CN or NH2;
B is selected from

### Claim 5 (depends on 4)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 4, wherein
L is selected from a bond, -Cy1-, -Cy1-Ak2-, -Cy1-Ak2-Ak3-, -Cy1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-, -Cy1-Ak2-Cy2-, -Cy1-Cy2-Ak3-, -Cy1-Cy2-Ak3-Cy4-, -Cy1-Ak2-Cy2-Ak3-, -Cy1-Ak2-Cy2-Ak3-Ak4-, -Cy1-Ak2-Cy2-Cy3-Ak4-, -Cy1-Cy2-Ak3-Ak4-, -Cy1-Cy2-Ak3-Ak4-Ak5-, -Cy1-Ak2-Cy2-Ak3-Ak4-Ak5-, -Cy1-Ak2-Ak3-Cy3-Ak4-, -Cy1-Ak2-Ak3-Cy3-Ak4-Ak5-, -Cy1-Ak2-Ak3-Ak4-Cy4-Ak5-, -Cy1-Cy2-Cy3-, -Cy1-Ak2-Cy2-Cy3-, -Cy1-Cy2-Cy3-Ak4-, -Cy1-Ak2-Cy2-Cy3-Ak4-, -Cy1-Ak2-Cy2-Ak3-Cy3-, -Cy1-Ak2-Cy2-Cy3-Ak4-Ak5, -Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak3-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak4-Cy4-, -Ak1-Cy1-Ak2-Cy2-, -Ak1-Cy1-Ak2-Cy2-Ak3-, -Ak1-Ak2-Cy2-Ak3-, -Ak1-Ak2-Cy2-, -Ak1-Ak2-Cy2-Cy3-Ak4-, -Ak1-Ak2-Ak3-Cy3-Ak4-, -Ak1-Cy1-Ak2-, -Ak1-Cy1-Cy2-Ak3-Ak4-, -Ak1-Cy1-Cy2-Ak3-, -Ak1-Cy1-Ak2-Ak3-Ak4-, -Ak1-Cy1-, -Ak1-Cy1-Ak2-Ak3-, -Ak1-Ak2-Cy2-Ak3-Ak4-, -Ak1-Cy1-Ak2-Cy2-Ak3-Ak4-, -Cy1-Ak2-Ak3-Cy3-Cy4-Ak5-, -Ak1-Cy1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-, -Ak1-Cy1-Cy2-, -Ak1-Ak2-Ak3-Ak4- or -Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-;
Ak1, Ak2, Ak3, Ak4 and Ak5 are each independently selected from O, C═C, CH2, CH2CH2, CH2CH2CH2, CH2CH2CH2CH2, CH2N(CH3), CH2CH2N(CH3), N(CH3), NH, C(═O), C(═O)N(CH3), N(CH3) C(═O), C(═O)NH or NHC(═O).

### Claim 6 (depends on 4)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 4, wherein
L is selected from
each J1 is independently selected from
each J2 is independently selected from
each J3 is independently selected from
each J4 is independently selected from
each J5 is independently selected from
or, L is selected from
Rd is selected from H or D, and at least one of Rd is selected from D;
d1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
d2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9.

### Claim 7 (depends on 4)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 4, wherein
L is selected from a group shown in Table L-1, wherein the left side of the group is linked to B.

### Claim 8 (depends on 5)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 5, wherein
K is selected from

### Claim 9 (depends on 1)

The compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 1, wherein the compound is selected from one of the structures shown in Table P-1.

### Claim 10 (depends on 1)

A pharmaceutical composition, comprising the compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof according to claim 1, and a pharmaceutically acceptable carrier, wherein preferably, the pharmaceutical composition comprises 1-1500 mg of the compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or eutectic crystal thereof.

### Claim 11 (depends on 1)

A method for treating a disease related to the activity or expression quantity of IRAK4 or a disease related to the inhibition or degradation of IRAK4 comprising administering to a subject the compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or eutectic crystal thereof according to claim 1.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method of claim 11, wherein the disease is selected from an autoimmune disease, an inflammatory disease or cancer.

### Claim 14 (depends on 1)

A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of the compound or the stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or eutectic crystal thereof according to claim 1.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the therapeutically effective amount is 1-1500 mg.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the disease is an autoimmune disease, an inflammatory disease or cancer.